Influence of Elevated LH: FSH Ratio on IVF Outcome, Comparing the Impacts of Different Triggering Medicines
Received Date: Sep 11, 2017 / Accepted Date: Sep 21, 2017 / Published Date: Sep 28, 2017
Objective: To study how elevated LH: FSH ratio influence IVF outcome in High response patients with different triggering medicines.
Design: This study was observational study performed in Medcare Fertility Centre, Dubai, UAE, between April 2016 to July 2017. Patients: 81 high ovarian response women (AMH ≥ 4 ng/ml and LH/FSH ≥ 1).
Main outcome: Measures the impact of high LH/FSH ratioo on IVF outcome in according to the triggering used.
Results: The LH/FSH ratio (when less than 1.5) has significant effect (p<0.05) on the total number of M2 oocytes and subsequently on the fertilization rates (IVF outcome) but no significant (p>0.05) effect on the number of total retrieved oocytes. But as LH/FSH ratio increases further (>1.5), all parameters significantly decreased. Furthermore, patients using uhcg (Pregnyl®) recorded higher number of matured oocytes retrieved (81%) and improves fertility rate (66%) while GnRHa (Gonapeptyl.01®) has better effectiveness (114%) only on the total number of oocytes retrieved and it has less rate of oocytes maturation comparable to uhcg (74% vs. 81%). Conclusion: This study observed that for high response patients, with LH/FSH ratio less than 1.5 has significant effect on total matured oocytes retrieved and subsequently the fertilization when we use of uhcg (Pregnyl®) as ovulation triggering medicine improves IVF outcome. Also, noted that when LH/FSH ratio more than 1.5, baseline characteristics parameters began to significantly decrease to find the triggering with GnRHa (Gonapeptyl.01®) proved to be better in the number of Oocytes retrieved and maturation rate of oocytes.
Keywords: High LH:FSH ratio; Human chorionic gonadotropin (HCG); Luteinising hormone(LH); Follicle stimulating hormone (FSH); In vitro fertilization (IVF); Ovulation triggering medicine; High ovarian response; Fertilization rate
The accurate measurement of FSH and LH levels on Cycle day 3, in patients with diagnosis and monitoring and in therapeutic preparations for clinical use, is essential for safe and successful treatment  and also crucial for the success of an IVF cycle. Women with LH and FSH concentrations within the normal limits and those with an elevated LH/FSH ratio are typically defined as ‘normal’ and ‘high’ responders respectively . Lenton et al. demonstrated that an increase in (FSH) occurs several years before (LH)  and elevated day 3 serum FSH/LH ratio may identify patients less likely to respond adequately to ovulation induction during IVF treatments. Patients with LH:FSH ratios were more likely to have highly responded to ovarian stimulation programme. The relative importance of LH/FSH ratio on fertilization rate is still debatable in the clinical settings . Liu et al. demonstrated that day 3 LH/FSH ≥ 2 is associated with higher rates of cancellation of IVF cycles since there was less expecting the number of Oocytes retrieved together with very poor maturation . The hypothesis in conducting the present study was to observe whether elevated day 3 LH/FSH ratio ≥ 1 and above in high response women are really impacting IVF outcome (total number of oocytes retrieved and Total matured oocytes) while using different triggering medicine for ovulation stimulation  (Figures 1 and 2).
Materials and Methods
This observational study was conducted using data accumulated in a single IVF centre (Medcare Fertility Clinic, Dubai). 81 high responder patients undergoing IVF program from April 2016 to July 2017 were available for review, and Institutional review board of Medcare Fertility Clinic approval was collected because this was an observational study which was not routinely done. The patients were stimulated and treated in the same clinic and by same physicians and Embryology team.
High responder women undergoing ovarian stimulation for IVF/ICSI cycle regardless the infertility factor. Patients (n=81) underwent ovarian stimulation by either GnRH Agonist Long Protocol (Gonapeptyl0.1, Ferring Pharmaceuticals, Germany) or GnRH antagonist protocol (Cetrorelix Acetate Injection®; Cetrotide®, Serono, Italy). Ovarian stimulation was administered as recombinant FSH (rFSH; Gonal-F®, Serono) alone or in combination with human menopausal Gonadotrophins (Menopure®, Ferring Pharmaceuticals, Kiel, Germany). However, the majority of the patients (n=59) ovulation stimulation protocol was the antagonist which was randomly prescribed to trigger the ovulation as part of an assisted reproductive cycle by using rHCG, uHCG or GnRHa. A total of 81 patients were eligible using the inclusion criteria for high responder undergoing ovarian stimulation cycles were recruited into this study. These criteria are:
• Age>36 years old.
• Hyper response when AMH<4 ng/ml (as per Medcare Laboratory references)
• LH/FSH ratio equal or more than 1 (basic on Cycle day 3)
Women with High Ovarian response (AMH<4 ng/mL) who underwent IVF treatment were divided into those with LH/FSH ratio (>1 to <1.5), (>1.5 to >2), (>2 to <2.5), (>2.5 to <3) and (LH/FSH>3).
The three groups of patients observed were:
• Group A (n=37) consisted of women triggered by Urinary HCG, Pregnyl® (Dose: 10.000 IU)
• Group B (n=25) comprised women triggered with recombinant HCG, Ovitrelle®
• Group C (n=19) consisted of women triggered by Agonist GnRH, Gonapeptyl0.1® (Dose: 0.2 mg/ml)
Serial vaginal ultrasonography for response monitoring and measurement of serum Estradiol level, stimulation sheets were well completed with considering the policies in the protocol used, when reaching the right time for triggering; the patients were randomly divided into three groups according to the triggering Medicine used.
In all groups, 35 h after triggering medicine injection; transvaginal ultrasound-guided oocyte retrieval by using a 17 gauge needle was performed. The numbers of retrieved oocytes were recorded. Standard laboratory protocols were followed and approximately two hours after retrieval the cumulus cells were removed and an assessment of oocytes maturity under an inverted microscope was made.
After triggering of ovulation and oocytes retrieval, for Fertilizing rate, we consider the number of 2PN (2 pro-nuclei) oocytes seen after 18 h from injecting by ICSI the whole number of matured oocytes retrieved. The patient with freeze all oocytes to avoid hyper stimulation syndrome, were consider and study after thawing. We did not calculate the 2PN oocytes which occurred after late maturation of oocytes at meiosis stage 1(M1).
Primary outcomes: It was to study the impact of the triggering Medicine on: (i) the total number of oocytes retrieved per number of aspirated follicles (more than 14 mm); and (ii) the total number of mature oocytes obtained; (maturation rates of oocytes was defined as the numbers of mature oocytes per numbers of total retrieved oocytes).
Secondary outcomes: It was to compare the impacts of the triggering medicine on fertilization rates regarding the LH:FSH ratio.
Statistical analysis was carried out using the statistical package for the social science (IBM SPSS version 20.0 for Windows). Chi-square test was used to detect significant differences (p<0.05) of the all variables.
In our study, 81 patients participated, and were divided, as mentioned above, into 3 groups, Group A (n=37) consisted of women triggered by Urinary HCG, Pregnyl®, Group B (n=25) comprised women triggered with recombinant HCG, Ovitrelle® and Group C (n=19) consisted of women triggered by GnRHa (Gonapeptyl0.1®) respectively. Baseline marks of patients observed include age, a total number of follicles <14 mm; total oocytes and mature oocytes retrieved were expressed in mean, standard error, median, standard deviation, minimum and maximum values, shown in Table 1.
|N=81||Age (years)||Number of follicles < 14 mm||Oocytes retrieved||Matured oocytes||2 PN||FSH||LH|
|Std. Error of mean||0.36||1.43||1.13||1.01||0.70||0.18||0.25|
Relationship of LH/FSH ratio to baseline characteristics
Table 1: Baseline characteristics of patients.
The LH/FSH ratio (>1 and <1.5) has significant (p<0.05) effect on total number of matured oocytes retrieved and subsequently on the fertilization rates (IVF outcome) (Tables 2 and 3) but no significant (p>0.05) effect on number of retrieved oocytes (Tables 4 and 5) and as LH/FSH ratio increases further (>1.5), all baseline characteristics parameters significantly decreased.
|Range||≤10||>10 ≤ 20||>20 ≤ 30||>30 ≤ 40||>50 ≤ 60||Total (n=81)|
|>1 ≤ 1.5||11||35||11||5||0||62|
|>1.5 ≤ 2||4||5||3||0||1||13|
|>2 ≤ 2.5||2||0||1||0||0||3|
|>2.5 ≤ 3||1||0||1||0||0||2|
LH/FSH ratio versus matured retrieved (p-value=significant)
Table 2: Total number of matured oocytes.
|Range||<10||>10 ≤ 20||>20 ≤ 30||> 40 ≤ 50||Total (n=81)|
|>1 ≤ 1.5||37||22||3||0||62|
|>1.5 ≤ 2||8||4||0||1||13|
|>2 ≤ 2.5||2||1||0||0||3|
|>2.5 ≤ 3||2||0||0||0||2|
LH/FSH ratio versus fertilized oocytes (p-value=significant)
Table 3: Number of fertilized oocytes.
|Range||<10||>10 ≤ 20||>20 ≤ 30||>30 ≤ 40||>50 ≤ 60||Total (n=81)|
|>1 ≤ 1.5||5||31||21||4||1||62|
|>1.5 ≤ 2||0||7||5||0||1||13|
|>2 ≤ 2.5||0||2||0||1||0||3|
|>2.5 ≤ 3||0||2||0||0||0||2|
LH/FSH ratio versus follicle retrieved (p-value=not significant)
Table 4: Total number of follicles ≤ 14 mm.
|Range||<10||>10 < 20||>20 < 30||>30 < 40||>40 < 50||>50 < 60||Total (n=81)|
Comment: LH/FSH ratio versus oocytes retrieved (p-value=not significant)
Table 5: Total number of oocytes retrieved.
Furthermore, patients using uHCG (Pregnyl®) recorded a higher number of matured oocytes retrieved (81%). while GnRHa (Gonapeptyl.01®) has better effectiveness (114%) on the total number of oocytes retrieved, a similar effect on oocytes maturation with rHCG (Ovitrelle®) (74%-75%), respectively; but with uHCG showed higher effectiveness in maturation rate in comparison to the others 81% (Table 6).
|Triggering medicine||N=81||Follicle||Oocytes||Matured oocytes||2 PN|
|Pregnyl||37||783||761 (97%)||615 (81%)||404 (66%)|
|Ovitrelle||25||413||432 (105%)||319 (74%)||201 (63%)|
|Gonapeptyl||19||545||621 (114%)||466 (75%)||273 (59%)|
Table 6: Effect of triggering medicine
For fertilizing rate (in checking 2PN) there was significance rate in using uHCG (66%) to decrease with the other Medicines ; HCG (63%) and GnRHa (59%) when we consider the fertilizing after thawing in most of our patients since we do not do fresh embryo transfer and fertilizing when trigger by Gonapeptyl® [7,8].
In this study, it was observed that the LH/FSH ratio (>1 and <1.5) has significant (p<0.05) effect Baseline featured of patients (total number of oocytes retrieved and matured oocytes) and subsequently on the fertilization rates (IVF outcome) and as LH/FSH ratio increases further (>1.5), all parameters significantly decreased which is similar to the finding by Prasad et al. , where he found that women with an elevated LH/FSH ratio ≥ 2 required higher doses of gonadotrophins and the outcome of IVF was poor in these patients and they had poor maturation rate, fewer retrieved oocytes and fewer pregnancy rates which we had not study it in this article. Also, this study finds an increase in LH/FSH ratio effect on IVF outcome is similar to that by Barroso et al.  and Shrim et al. , which reported similar results in patients with elevated LH/FSH ratio >3. Also from this study, GnRHa (Gonapeptyl.01®) has better effectiveness (114%) on total number of oocytes retrieved than other triggering medicine as well as similar effectiveness in stimulating oocytes maturation as uHCG (75% to 81%) which is in agreement with the concept by Shahar and Peter, 2013 which suggested that a 0.2 mg of gonadotrophin-releasing hormone agonist (GnRHa) can replace human chorionic gonadotrophin (HCG) as a trigger of final oocyte maturation and that GnRHa trigger offers important advantages, including significant prevention of ovarian hyperstimulation syndrome (OHSS), safety and comfort of patients. The benefit of GnRHa was also emphasized by Humaidan et al. , that GnRHa triggering is more physiological, resembling the natural midcycle surge of gonadotropins, without the extended action of HCG, resulting in luteal phase steroid levels closer to those of the natural cycle and the reported retrieval of more mature oocytes when compared with HCG triggering. GnRHa triggering significantly reduces or eliminates the OHSS risk after ovarian stimulation for IVF/ICSI in comparison with hCG triggering.
Moreover, Humaidan et al.  showed in a randomized controlled trial that more metaphase II oocytes were obtained after GnRHa trigger compared with after HCG trigger, which came similarly in our study.
This study observed that LH/FSH ratio between the range of >1 to <1.5 has significant effect on total matured oocytes retrieved and subsequently the fertilization (IVF outcome) in high response patients and also noted that at LH/FSH ratio increases (>1.5), baseline characteristics parameters began to significantly decrease; i.e., at higher LH/FSH (>1.5) ratio fertilization rate (IVF outcome) decreases . Also, all triggering medicines had an effect on ovulation induction but GnRHa (Gonapeptyl.01®) proved to be better in collecting the higher number of oocytes from the total number of follicles; and has a similar effect for maturation of oocytes. The use of uHCG (Pregnyl®) as ovulation triggering medicine improves IVF outcome.
Implications for Research
More research and wide analysis is needed to assess the influence of elevated LH/FSH ratio on IVF pregnancy rate comparing with patient with normal hormones profile.
I would like to thank Medcare Fertility Clinic-Dubai and all patients who participated in this study.
- Jeffcoate SL (1994) From TNA to DNA: 60 years of follicle stimulating hormone (FSH) in gynaecology. The Yearbook of the RCOG. R Coll Obstet Gynecol Lond, pp: 55-67.
- Muasher SJ, Oehninger S, Simonetti S, Matta J, Ellis LM, et al. (1988) The value of basal and/or stimulated serum gonadotropin levels in prediction of stimulation response and in vitro fertilization outcome. Fertil Steril 50: 298-307.
- Lenton EA, Sexton L, Lee S, Cooke ID (1988) Progressive changes in LH and FSH and LH:FSH ratio in women throughout reproductive life. Maturitas 10: 35-43.
- Lévy DP, Navarro JM, Schattman GL, Davis OK, Rosenwaks Z (2000) The role of LH in ovarian stimulation: Exogenous LH: Let's design the future. Hum Reprod 15: 2258-2265.
- Liu KE, Greenblatt EM (2008) Elevated day 3 follicle stimulating hormone/luteinizing hormone ratio >or=2 is associated with higher rates of cancellation in in vitro fertilization-embryo transfer cycles. Fertil Steril 90: 297-301.
- Kol S, Humaidan P (2013) GnRH agonist triggering: recent developments. Reprod Biomed Online 26: 226-230.
- Barroso G, Oehninger S, Monzó A, Kolm P, Gibbons WE et al. (2001) High FSH:LH ratio and low LH levels in basal cycle day 3: Impact on follicular development and IVF outcome. J Assist Reprod Genet 18: 499-505.
- Humaidan P, Kol S, Papanikolaou EG (2011) GnRH agonist for triggering of final oocyte maturation: Time for a change of practice? Hum Reprod Update 17: 510-524.
- Prasad S, Gupta T, Divya A (2013) Correlation of the day 3 FSH/LH ratio and LH concentration in predicting IVF outcome. J Reprod Infertil 14: 23-28.
- Shrim A, Elizur SE, Seidman DS, Rabinovici J, Wiser A, et al. (2006) Elevated day 3 FSH/LH ratio due to low LH concentrations predicts reduced ovarian response. Reprod Biomed Online 12: 418-422.
- Griesinger G, Diedrich K, Devroey P, Kolibianakis EM (2006) GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: A systematic review and meta-analysis. Hum Reprod Update 12: 159-168.
Citation: Khrait Z (2017) Influence of Elevated LH: FSH Ratio on IVF Outcome, Comparing the Impacts of Different Triggering Medicines. JFIV Reprod Med Genet 5: 204. Doi: 10.4172/2375-4508.1000204
Copyright: © 2017 Khrait Z. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
21st Euro Biotechnology Congress
October 11-12, 2018 Moscow, Russia
Annual Conference on Biomaterials for Bone Tissue Engineering
October 18-19, 2018 Dubai, UAE
11th International Conference on Tissue Engineering & Regenerative Medicine
October 18-20, 2018 Rome, Italy
24th Biotechnology Congress: Research & Innovations
October 24-25, 2018 Boston, USA
International Conference on Human Genome Meeting
October 25-26, 2018 Istanbul, Turkey
International Congress & Expo on Genomics and Bioinformatics
November 2-3, 2018 Columbus, USA
12th International Conference & Exhibition on Tissue Preservation and Biobanking
April 23-24, 2018 Las Vegas, USA
- Total views: 1023
- [From(publication date): 0-2017 - Aug 18, 2018]
- Breakdown by view type
- HTML page views: 957
- PDF downloads: 66